IMMUNOREA - Immunological and Inflammatory Determinants Associated With the Prognosis of Intensive Care Patients

ConditionsCritical Illness Intensive Care Patients Critical Illness Requiring Intensive Care - Sepsis Critical Illness Requiring Intensive Care - Acute Brain Injury Critical Illness Requiring Intensive Care - Major Surgery Critical Illness Requiring Intensive Care - Polytrauma

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorAssistance Publique - Hôpitaux de Paris

About this trial

This is a prospective observational physiopathological study aimed at evaluating the immunological and inflammatory determinants associated with the prognosis of patients admitted to intensive care units (ICU). The study will establish multidimensional models predicting one-year survival and the occurrence of nosocomial infections.

Patients admitted to ICU undergo routine biological sampling. In addition to these, minimal supplementary samples will be collected for immunological and inflammatory biomarker analysis at admission, day 1, day 4, day 8, ICU discharge or day 28, and at 12 months. Additional samples may be taken during clinically significant events (nosocomial infections, complications).

Eligibility criteria

Qualifiers

Age ≥ 18 years

Admission to ICU within 24 hours

Disqualifiers

Moribund patient (ECOG=4)

Legal protection (guardianship/curatorship)

Uninsured patients

Pre-existing immunosuppression (active/recent cancer, hematologic disease, autoimmune disease, organ transplant, HIV)

Trial design

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

Assistance Publique - Hôpitaux de Paris

Lead sponsor

INSERM U942

Collaborator

Société Française d'Anesthésie et de Réanimation

Collaborator

French Society for Intensive Care

Collaborator

European Society of Intensive Care Medicine

Collaborator

ZOLL Foundation, Fondation Les Gueules Cassées

Collaborator

Source ClinicalTrials.gov